Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Managed Access Program Cohort Treatment Plan CTMT212X2002I to Provide Access to Trametinib and Dabrafenib Combination Therapy for Patients With BRAF V600 Mutation-positive Advanced Non-Small Cell Lung Cancer

Conditions: Small Cell Lung Carcinoma

First Posted Date: 2020-08-11

Last Posted Date: 2024-11-11

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04507919

MAP to Provide Access to Nilotinib, for Patients With HES

Conditions: Hypereosinophilic Syndrome (HES)

First Posted Date: 2020-08-05

Last Posted Date: 2021-09-20

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04498871

Effective Study of ARNI on Ventricular Arrhythmia in HFrEF Patients With ICD or CRT-D (RHYTHM)

Phase 4

Terminated

Conditions: Heart Failure

Interventions: Drug: ACEI/ARB
Drug: ARNI

First Posted Date: 2020-07-29

Last Posted Date: 2025-05-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 201

Registration Number: NCT04491136

Locations: 🇨🇳
Novartis Investigative Site, Tianjin, China

Compassionate Use Program to Access Trametinib and Dabrafenib for Patients With BRAF Mutation-positive Metastatic Melanoma

Conditions: Melanoma

First Posted Date: 2020-07-28

Last Posted Date: 2024-02-08

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04489433

A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple Sclerosis

Phase 3

Completed

Conditions: Relapsing Multiple Sclerosis

Interventions: Drug: Ofatumumab

First Posted Date: 2020-07-27

Last Posted Date: 2025-03-17

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 111

Registration Number: NCT04486716

Locations: 🇺🇸
Sibyl Wray MD Neurology PC, Knoxville, Tennessee, United States
🇺🇸
Alabama Neurology Associates PC, Birmingham, Alabama, United States
🇺🇸
Ctr for Neurology and Spine, Phoenix, Arizona, United States

and more 17 locations

An Efficacy Study of Secukinumab in Plaque Psoriasis Patients With Subclinical Psoriatic Arthritis as Measured by Musculoskeletal Ultrasound

Phase 4

Withdrawn

Conditions: Psoriasis

Interventions: Other: Placebo
Biological: Secukinumab 300 mg

First Posted Date: 2020-07-27

Last Posted Date: 2023-03-31

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04488185

Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis

Phase 4

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Fingolimod

First Posted Date: 2020-07-21

Last Posted Date: 2024-12-27

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT04480853

Locations: 🇨🇳
Novartis Investigative Site, Taoyuan, Taiwan

Canakinumab MAP in COVID-19 Pneumonia With CRS

Conditions: Cytokine Release Syndrome in COVID-19-induced Pneumonia

First Posted Date: 2020-07-20

Last Posted Date: 2021-02-03

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04476706

Managed Access Program to Provide Access to Alpelisib for Patients With Advanced Breast Cancer

Conditions: HR+, HER2-, Advanced Breast Cancer

First Posted Date: 2020-07-16

Last Posted Date: 2024-10-29

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04473040

A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases

Phase 2

Withdrawn

Conditions: Non-small Cell Lung Carcinoma (NSCLC)

Interventions: Drug: Capmatinib

First Posted Date: 2020-07-08

Last Posted Date: 2020-12-03

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT04460729

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy